When it comes to treating cognitive decline, getting an accurate diagnosis is half the battle. On August 14, 2026, the diagnostic toolkit for Alzheimer’s disease got a major upgrade. The FDA officially approved Tauklarify (florquinitau F 18 injection), a specialized radiodiagnostic agent from Lantheus Holdings designed specifically for Positron Emission Tomography (PET) brain imaging.
By allowing doctors to literally see the physical footprints of Alzheimer’s disease inside a living patient's brain, Tauklarify is paving the way for more precise care and better treatment matching. Let's break down how this innovative imaging agent works and why it matters.
Tauklarify—previously known in clinical trials as MK-6240—is a radioactive diagnostic drug administered via a single intravenous injection before a PET scan. It acts as a targeted dye for the brain.
It is officially indicated for adults with cognitive impairment who are currently being evaluated for Alzheimer's disease. Importantly, it makes Lantheus the provider of only the second FDA-authorized tau PET tracer on the market.
To understand Tauklarify, we have to look at what Alzheimer's disease actually does to the brain. One of the primary biological hallmarks of Alzheimer's is the buildup of twisted protein fibers called tau neurofibrillary tangles (NFTs).
Here is how Tauklarify helps:
The FDA’s approval of Tauklarify was backed by extensive clinical data. The decision rested on two blinded read studies that analyzed brain scans from over 600 individuals. These trials included a mix of people with mild cognitive impairment, mild Alzheimer's dementia, and those who were cognitively unimpaired.
During the safety evaluations across more than 1,700 individuals, the agent was shown to be well-tolerated, with a mild headache being the most commonly reported side effect (occurring in just 0.7% of patients).
While this is a massive step forward, Tauklarify isn't a standalone magic bullet for diagnosis. The FDA carries specific limitations of use:
Instead, Tauklarify is intended to be used as a powerful collaborative tool alongside clinical evaluations, amyloid PET scans, and blood-based biomarkers.
With over 7 million people in the United States living with Alzheimer's disease—a number expected to surge past 13 million by 2050—advanced diagnostics have never been more critical. By granting doctors broader access to tau PET imaging, tools like Tauklarify not only support earlier and more precise diagnoses for families today but also help screen patients for the clinical trials that will create the breakthrough treatments of tomorrow.
Sources Referenced: